Solifenacin Succinate Tablets IP 10 Mg – Kelvoria 10 Tablets

Kelvoria 10 Tablets
Composition:- Solifenacin Succinate 10 mg

Kelvoria 10 Tablets contains Solifenacin Succinate Tablets IP 10 mg, a competitive and selective muscarinic M3 receptor antagonist. Blocking M3 receptors on the detrusor muscle, it inhibits involuntary bladder contractions and increases bladder capacity. It is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urinary frequency, and urgency urinary incontinence in adults who require higher-dose therapy.

Marketed by: Wonne International Pvt. Ltd.

Key points of Solifenacin Succinate Tablets IP 10 Mg – Kelvoria 10 Tablets

• Maximum therapeutic dose — 10 mg is the highest approved dose of Solifenacin, providing superior detrusor relaxation and symptom control in moderate-to-severe OAB.
• Selective M3 antagonism — Affinity for bladder M3 receptors over salivary gland receptors reduces systemic anticholinergic burden compared to non-selective agents.
• Sustained 24-hour efficacy — Long elimination half-life (45–68 hours) ensures consistent plasma levels and round-the-clock bladder control with once-daily dosing.

Can be Prescribed by:

• Urology
• Urogynaecology
• General Practice
• Geriatrics

Disclaimer: To be used under medical supervision only and not intended for general public promotion. This content is meant for registered healthcare professionals only.